With the addition of Bio-Prodict B.V. now zeven European Biotech SMEs form the Enzyme Technology Alliance to offer protein and enzymatic process R&D from early discovery to chemical manufacturing across the entire value chain
The demand for sustainable yet scalable protein solutions is rising in the Pharmaceutical and Industrial Biotechnology sectors worldwide. The journey from a DNA or protein sequence to a valuable chemo-enzymatic process to deploy at scale requires broad expertise in R&D and manufacturing to bring such projects to success.
The in 2022 formed Enzyme Technology Alliance allows start-ups and corporations globally to access the full scope of protein development to marketable products. Founders and members of the Enzyme Technology Alliance are the technologically complementary biotech-SMEs Candidum GmbH, Aminoverse B.V., ChiralVision B.V., Enzymicals AG, Spinchem AB and Allozymes comprising over 60 scientific experts and more than 175 years of combined experience ranging from enzyme discovery to facilitating cGMP enzymatic production of APIs.
Under the framework of the Enzyme Technology Alliance, the independent partners jointly tackle complex development projects spanning from in-silico catalyst discovery over AI-supported enzyme engineering to catalyst immobilization, DOE-based process intensification and scale-up. Like interlocking pieces of a puzzle, the strengths of each member are combined not only to create a new point of contact for the biotech industry but offer competitive solutions for both superior proteins and chemical entities.
